• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对描述健康波动的1年健康状况的整体偏好:以慢性阻塞性肺疾病为例。

Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease.

作者信息

Rutten-van Mölken Maureen P M H, Hoogendoorn Martine, Lamers Leida M

机构信息

Erasmus MC, Institute for Medical Technology Assessment (iMTA), Rotterdam, the Netherlands.

出版信息

Pharmacoeconomics. 2009;27(6):465-77. doi: 10.2165/00019053-200927060-00003.

DOI:10.2165/00019053-200927060-00003
PMID:19640010
Abstract

BACKGROUND

There are few empirical studies on the valuation of health profiles that describe the short-term fluctuations of chronic diseases.

OBJECTIVE

This study aimed to value chronic obstructive pulmonary disease (COPD) health profiles, which describe the health of these patients over the course of 1 year from a societal perspective.

METHODS

We developed 16 COPD health profiles. Each profile combined a description of the severity of COPD during the stable phase with a description of the exacerbation profile in terms of severity, frequency and duration. These profiles were valued by a representative sample of 239 Dutch adults using the visual analogue scale (VAS) and time trade-off (TTO) methods. Value functions were estimated using random effects regression analysis.

RESULTS

Both VAS and TTO values consistently decreased as severity of the COPD profiles increased. Estimated TTO values ranged from 0.97 for mild COPD without exacerbations to 0.43 for very severe COPD with one non-serious and one serious exacerbation per year. The estimated decrements in TTO values ranged from 0.010 for having one non-serious exacerbation to 0.088 for having one non-serious plus one serious exacerbation per year.

CONCLUSIONS

The value function may be an alternative way to model the joint impact of COPD severity and exacerbations on utility values in health economic modelling studies.

摘要

背景

关于描述慢性病短期波动的健康状况评估的实证研究较少。

目的

本研究旨在评估慢性阻塞性肺疾病(COPD)的健康状况,从社会角度描述这些患者一年中的健康状况。

方法

我们制定了16种COPD健康状况。每种状况都结合了稳定期COPD严重程度的描述以及急性加重状况在严重程度、频率和持续时间方面的描述。这些状况由239名荷兰成年人组成的代表性样本使用视觉模拟量表(VAS)和时间权衡(TTO)方法进行评估。使用随机效应回归分析估计价值函数。

结果

随着COPD状况严重程度的增加,VAS和TTO值均持续下降。估计的TTO值范围从无急性加重的轻度COPD的0.97到每年有一次非严重和一次严重急性加重的极重度COPD的0.43。TTO值的估计下降幅度范围从每年有一次非严重急性加重的0.010到每年有一次非严重加一次严重急性加重的0.088。

结论

在健康经济建模研究中,价值函数可能是一种模拟COPD严重程度和急性加重对效用值联合影响的替代方法。

相似文献

1
Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease.对描述健康波动的1年健康状况的整体偏好:以慢性阻塞性肺疾病为例。
Pharmacoeconomics. 2009;27(6):465-77. doi: 10.2165/00019053-200927060-00003.
2
Utility estimation of hypothetical chronic obstructive pulmonary disease health states by the general population and health professionals.普通人群和健康专业人员对假设的慢性阻塞性肺疾病健康状态的效用估计。
Health Qual Life Outcomes. 2015 Mar 13;13:34. doi: 10.1186/s12955-015-0228-2.
3
Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.开发一种经济模型以评估慢性阻塞性肺疾病治疗干预措施的成本效益。
Pharmacoeconomics. 2005;23(6):619-37. doi: 10.2165/00019053-200523060-00008.
4
Impact of mild exacerbation on COPD symptoms in a Japanese cohort.轻度加重对日本队列中慢性阻塞性肺疾病(COPD)症状的影响。
Int J Chron Obstruct Pulmon Dis. 2016 Jun 9;11:1269-78. doi: 10.2147/COPD.S105454. eCollection 2016.
5
[Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].[2007年波兰多中心研究中慢性阻塞性肺疾病加重期在初级和二级医疗保健中的费用]
Pol Merkur Lekarski. 2009 Mar;26(153):208-14.
6
Exacerbations of Chronic Obstructive Pulmonary Disease and Quality of Life of Patients.慢性阻塞性肺疾病急性加重与患者生活质量
Adv Exp Med Biol. 2016;884:69-74. doi: 10.1007/5584_2015_178.
7
Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.罗氟司特对慢性阻塞性肺疾病(COPD)急性加重、医疗保健利用及成本的影响:以老年医保优势人群为主的研究
Int J Chron Obstruct Pulmon Dis. 2015 Mar 16;10:565-76. doi: 10.2147/COPD.S79025. eCollection 2015.
8
Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.基于经验的瑞典 TTO 和 EQ-5D-5L 健康状态下的 VAS 值集。
Pharmacoeconomics. 2020 Aug;38(8):839-856. doi: 10.1007/s40273-020-00905-7.
9
Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis.中重度慢性阻塞性肺疾病(COPD)患者的支持性自我管理:证据综合与经济分析
Health Technol Assess. 2015 May;19(36):1-516. doi: 10.3310/hta19360.
10
The costs of exacerbations in chronic obstructive pulmonary disease (COPD).慢性阻塞性肺疾病(COPD)急性加重的成本。
Respir Med. 2002 Sep;96(9):700-8. doi: 10.1053/rmed.2002.1334.

引用本文的文献

1
Associations between the EQ-5D-5L and exacerbations of chronic obstructive pulmonary disease in the ETHOS trial.ETHOS 试验中 EQ-5D-5L 与慢性阻塞性肺疾病加重的相关性。
Qual Life Res. 2024 Apr;33(4):1029-1039. doi: 10.1007/s11136-023-03582-z. Epub 2024 Jan 11.
2
Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China.固定剂量噻托溴铵/奥达特罗与噻托溴铵治疗中国 COPD 患者的成本效果分析。
Int J Chron Obstruct Pulmon Dis. 2023 Sep 21;18:2093-2103. doi: 10.2147/COPD.S425409. eCollection 2023.
3
Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.

本文引用的文献

1
Evaluating equivalency between response systems: application of the Rasch model to a 3-level and 5-level EQ-5D.评估反应系统之间的等效性:Rasch模型在3级和5级EQ-5D中的应用。
Med Care. 2007 Sep;45(9):812-9. doi: 10.1097/MLR.0b013e31805371aa.
2
Health status impairment and costs associated with COPD exacerbation managed in hospital.因慢性阻塞性肺疾病急性加重而住院治疗所导致的健康状况损害及费用。
Int J Clin Pract. 2007 Jul;61(7):1112-20. doi: 10.1111/j.1742-1241.2007.01424.x.
3
Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
布地奈德/格隆溴铵/富马酸福莫特罗二水化合物三联疗法与中重度至极重度慢性阻塞性肺疾病的双重疗法相比的成本效益:ETHOS 研究的英国分析。
Int J Chron Obstruct Pulmon Dis. 2022 Nov 22;17:2987-3000. doi: 10.2147/COPD.S381138. eCollection 2022.
4
Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China.乌美溴铵/维兰特罗与沙美特罗/氟替卡松治疗中国老年慢性阻塞性肺疾病患者的成本-效果分析。
Int J Chron Obstruct Pulmon Dis. 2022 Mar 22;17:609-619. doi: 10.2147/COPD.S350218. eCollection 2022.
5
Cost-Effectiveness Analysis of Triple Combination Preparations in the Treatment of Moderate-to-Severe Chronic Obstructive Pulmonary Disease.三联制剂治疗中重度慢性阻塞性肺疾病的成本效益分析。
Front Public Health. 2021 Jul 28;9:713258. doi: 10.3389/fpubh.2021.713258. eCollection 2021.
6
Cost Effectiveness of Case Detection Strategies for the Early Detection of COPD.COPD 早期检测的病例发现策略的成本效益。
Appl Health Econ Health Policy. 2021 Mar;19(2):203-215. doi: 10.1007/s40258-020-00616-2. Epub 2020 Nov 2.
7
Using a Health Economic Framework to Prioritize Quality Indicators: An Example With Smoking Cessation in Chronic Obstructive Pulmonary Disease.运用健康经济框架对质量指标进行优先级排序:以慢性阻塞性肺疾病戒烟为例。
MDM Policy Pract. 2019 May 27;4(1):2381468319852358. doi: 10.1177/2381468319852358. eCollection 2019 Jan-Jun.
8
Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada.加拿大 Aerobika®振荡正压呼气装置在慢性阻塞性肺疾病加重管理中的成本效益。
Can Respir J. 2019 Jan 10;2019:9176504. doi: 10.1155/2019/9176504. eCollection 2019.
9
Do time trade-off values fully capture attitudes that are relevant to health-related choices?时间权衡值是否完全捕捉到与健康相关选择相关的态度?
Eur J Health Econ. 2019 Jun;20(4):559-568. doi: 10.1007/s10198-018-1017-8. Epub 2018 Dec 31.
10
What should we know about the person behind a TTO?关于技术转让办公室(TTO)背后的人我们应该了解些什么?
Eur J Health Econ. 2018 Dec;19(9):1207-1211. doi: 10.1007/s10198-018-0975-1.
采用通用的欧洲五维健康量表问卷测量的慢性阻塞性肺疾病(COPD)患者的生活质量能否区分COPD的严重程度阶段?
Chest. 2006 Oct;130(4):1117-28. doi: 10.1378/chest.130.4.1117.
4
Economic modeling in chronic obstructive pulmonary disease.慢性阻塞性肺疾病的经济模型
Proc Am Thorac Soc. 2006 Sep;3(7):630-4. doi: 10.1513/pats.200603-095SS.
5
The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies.荷兰关税:国家EQ-5D估值研究有效设计的结果与论据
Health Econ. 2006 Oct;15(10):1121-32. doi: 10.1002/hec.1124.
6
Inconsistencies in TTO and VAS values for EQ-5D health states.EQ-5D健康状态的时间权衡法(TTO)和视觉模拟评分法(VAS)值的不一致性。
Med Decis Making. 2006 Mar-Apr;26(2):173-81. doi: 10.1177/0272989X06286480.
7
Does the whole equal the sum of the parts? Patient-assigned utility scores for IBS-related health states and profiles.整体是否等于部分之和?肠易激综合征相关健康状态和概况的患者指定效用评分。
Health Econ. 2006 Jun;15(6):543-51. doi: 10.1002/hec.1074.
8
The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature.质量调整生命年模型以及随时间推移个体对健康状态和健康状况的偏好:文献系统综述
Med Decis Making. 2005 Jul-Aug;25(4):460-7. doi: 10.1177/0272989X05276854.
9
Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.开发一种经济模型以评估慢性阻塞性肺疾病治疗干预措施的成本效益。
Pharmacoeconomics. 2005;23(6):619-37. doi: 10.2165/00019053-200523060-00008.
10
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.N-乙酰半胱氨酸对慢性阻塞性肺疾病预后的影响(N-乙酰半胱氨酸成本-效用研究中的支气管炎随机试验,BRONCUS):一项随机安慰剂对照试验
Lancet. 2005;365(9470):1552-60. doi: 10.1016/S0140-6736(05)66456-2.